Indivior Pharmaceuticals, Inc.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. carries a market capitalization of 4.22B, placing it among publicly traded companies globally. Its enterprise value stands at 4.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Indivior Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. has 118.00M shares outstanding.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 14.18. The price-to-sales ratio is 3.78, and the price-to-book ratio stands at -23.32.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 11.67 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.48B versus a market cap of 4.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. maintains a current ratio of 0.84, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -245.89, indicating conservative leverage, while an interest coverage ratio of 16.22 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 157.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 26.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 185.07, useful for judging operating efficiency across full business cycles. The company generates approximately 1.31M in revenue per employee across its workforce of 891.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.60 indicates how many times Indivior Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Indivior Pharmaceuticals, Inc. recorded 33.26M in income tax expense. That works out to an effective tax rate of 9.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 343.99M, leaving 310.73M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Indivior Pharmaceuticals, Inc. generated 1.17B in revenue and converted that into 310.73M in net income, yielding earnings per share of 2.44. EBITDA reached 383.38M, while operating income came in at 370.25M.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. holds 194.32M in cash and equivalents against 445.53M in total debt, resulting in a net debt position of 231.95M. Total book value stands at -181.19M, with working capital of -125.17M providing operational flexibility.

Indivior Pharmaceuticals, Inc. produced -35.01M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -62.15M in capital expenditures, free cash flow totaled -97.16M - equivalent to -0.79 per share.

Over the twelve months ended June 30, 2026, Indivior Pharmaceuticals, Inc. posted a gross margin of 81.98, reflecting its pricing power and cost economics. The operating margin of 31.76 and net profit margin of 26.65 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Indivior Pharmaceuticals, Inc. shareholders.

Indivior Pharmaceuticals, Inc.'s most recent stock split took place on October 11, 2022 with a 5:1 split ratio.

As of June 30, 2026, Indivior Pharmaceuticals, Inc. has an Altman Z-Score of 3.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.